Core Insights - The article highlights the advancements in remote surgical technology, particularly the world's first remote robot-assisted retinal injection surgery conducted by Zhongshan University Eye Center, marking a significant breakthrough in the field of eye health by 2025 [1][6] - The establishment of a separate pricing category for remote surgical assistance by the National Medical Insurance Administration indicates a push towards upgrading medical technology and improving accessibility for patients, especially in remote areas [1][6] Group 1: Technological Innovations - The remote robot-assisted surgery can perform precise operations within 7 minutes, showcasing the potential of advanced technology in enhancing surgical efficiency and accuracy [1] - The ChatZOC eye model, developed in collaboration with Huawei, is being piloted in rural areas, demonstrating the application of AI in diagnosing and preventing eye diseases [2] - The integration of a flying eye hospital with advanced technology aims to provide comprehensive eye care services across various terrains, including air, land, and sea [3] Group 2: Drug Development - Zhongshan University Eye Center has developed groundbreaking eye medications, including the world's first eye drops capable of reversing cataracts and new glaucoma treatments, which are currently in phase III clinical trials [4][5] - The center emphasizes the importance of understanding disease mechanisms to create effective treatments, indicating a strong focus on research and development in the pharmaceutical sector [5] Group 3: Policy and Infrastructure - The center's initiatives align with the Guangdong government's focus on enhancing children's eye health, reflecting a growing awareness and proactive measures in the community [7] - Recommendations made during the Guangdong Two Sessions include accelerating the development of flying eye hospitals and improving policies for technology transfer, aiming to bridge the gap between innovation and practical application [8][9] - The establishment of a comprehensive industrial system from drug development to technology platforms is envisioned, positioning the center as a hub for medical innovation in the Guangdong-Hong Kong-Macao Greater Bay Area [10]